New Agent May Prevent Diabetic Nephropathy

Share this content:

Utah researchers report success with a new agent for preventing diabetic nephropathy. The agent is called atrasentan and it is a highly selective endothelin-A receptor (ETAR) agonist. John Schieszer has the story in today's Medical Minute.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters